Inspired by the Kingdom of Saudi Arabia's Vision 2030, Keuro Life aims to become one of the most trusted pharmaceutical companies in the Kingdom. Keuro Life is dedicated to localizing research and development (R&D) and drug manufacturing. We will establish a state-of-the-art R&D facility and manufacturing plant in the Kingdom of Saudi Arabia to produce high-quality "Made in Saudi" products for both local and international markets.
0
Biosimilars
0
Oncology
0
Immuno-Suppressants
0
Hormones
0
Softgels
0
General Category & Anti-Infective
The manufacturing facility spans a total plot area of 27,500 sq meters and a buildup area of 23,500 sq meters. It boasts an impressive annual capacity to produce over 800 million dosages. The facility includes a dedicated containment blocks.
A 1,000 square meter R&D center is planned for the site, commencing in April 2027. This center will facilitate product development and analysis, stability and scaling studies, pharmacodynamics study on new molecules, technology transfer, and pilot-scale batch manufacturing. In the mean time we have started our Product Development activities with our Joint Venture Partners in India and China, whose facilities are approved by USFDA/EU authorities.
Keuro Life Quality Control (QC)– Testing Laboratory is equipped with cutting-edge instruments and advanced technology to ensure precision, reliability, and compliance with industry standards.
Pharmaceutical cleanrooms are designed to provide a controlled environment as specified by approved FDA validation and CGMP practice. The modular cleanroom is optimized to create a sterile manufacturing environment for the pharmaceutical products. Filling rooms are typically ISO5 class 100.
To prevent any kind of cross contamination and reduce human intervention.
100% paperless record for manufacturing, packaging & analytical batch records.
Automated packaging line, with track & trace technology, to identify each and every product along the value chain at any point of time, including the warehouse.